Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Notes Receivable: ¥0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688443 Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
65 GF Score
Price ¥23.25
GF Value ¥286.64
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Chongqing Genrix Biopharmaceutical Co Notes Receivable?

Chongqing Genrix Biopharmaceutical Co SHSE:688443 -1.23% 65 Notes Receivable is ¥0.0 Mil as of Jun. 2026. GuruFocus rates SHSE:688443 with a GF Score™ of 65/100 and a GF Value™ of ¥286.64 (Possible Value Trap). The stock has 5 warning signs investors should review.

Chongqing Genrix Biopharmaceutical Co's Notes Receivable for the quarter that ended in Jun. 2026 was ¥0.0 Mil.

Chongqing Genrix Biopharmaceutical Co Notes Receivable Related Terms

Chongqing Genrix Biopharmaceutical Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Genrix Biopharmaceutical Co Notes Receivable Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688443
65GF Score
Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Genrix Biopharmaceutical Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0.0 Mil mean?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Notes Receivable of ¥0.0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors.
Is Chongqing Genrix Biopharmaceutical Co's Notes Receivable too high?
Chongqing Genrix Biopharmaceutical Co's current Notes Receivable is ¥0.0 Mil. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Notes Receivable compare to VRTX and REGN?
Chongqing Genrix Biopharmaceutical Co's Notes Receivable of ¥0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. Chongqing Genrix Biopharmaceutical Co's current Notes Receivable is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co (SHSE:688443) is currently considered Possible Value Trap. The stock's GF Value™ is ¥286.64, compared to a current price of ¥23.25 — trading 91.9% below its estimated fair value. The current Notes Receivable is ¥0.0 Mil. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Notes Receivable is ¥0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Overvalued in 2026?

Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co stock appears to be undervalued. The current stock price of ¥23.25 is trading 91.9% below its estimated GF Value™ of ¥286.64. GuruFocus considers Chongqing Genrix Biopharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:688443:

  • Notes Receivable: ¥0.0 Mil
  • GF Value™: ¥286.64 vs. price of ¥23.25 (91.9% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688443 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chongqing Genrix Biopharmaceutical Co Business Description

Address No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan District, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
65GF Score

Get the complete analysis for SHSE:688443

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.25
Price
¥286.64
GF Value